Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.74 |
| ▸ | EBP | Q15125 | 1/20 | 0.63 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8013750 | 0.91 | SIGMAR1 (0.83) | SIGMAR1EBPSLC18A3ALDH1A1TP53 | |
| SCHEMBL14298470 | 0.85 | SIGMAR1 (0.74) | SIGMAR1EBPSLC18A3ALDH1A1TP53 | |
| SCHEMBL7381325 | 0.85 | SIGMAR1 (1.00) | SIGMAR1EBPSLC18A3ALDH1A1TP53 | |
| SCHEMBL6396099 | 0.85 | SIGMAR1 (0.74) | SIGMAR1EBPSLC18A3ALDH1A1TP53 | |
| SCHEMBL13963562 | 0.83 | SIGMAR1 (0.76) | SIGMAR1EBPSLC18A3ALDH1A1TP53 | |
| SCHEMBL7382266 | 0.83 | SIGMAR1 (1.00) | SIGMAR1EBPSLC18A3ALDH1A1TP53 | |
| SCHEMBL8557477 | 0.82 | SIGMAR1 (0.84) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL12120510 | 0.82 | SIGMAR1 (0.69) | SIGMAR1EBPALDH1A1TP53CYP1A2 | |
| SCHEMBL6396812 | 0.82 | SIGMAR1 (0.58) | SIGMAR1EBPSLC18A3OPRL1OPRK1 | |
| Hydrochloric Acid SCHEMBL7382940 | 0.82 | SIGMAR1 (1.00) | SIGMAR1EBPSLC18A3ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | ANDO KOJI (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1399432-A1 | SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030078279-A1 | Spiropiperidine compounds as ligands for ORL-1receptor | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030078278-A1 | Spiropiperidine compounds as ligands for ORL-1 receptor | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003000677-A1 | SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER PHARMACEUTICALS INC. (JP) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078278-A1 | Spiropiperidine compounds as ligands for ORL-1 receptor | OPRL1, OPRD1, OXER1 | SIGMAR1 9/4885EBP 1902/4885SLC18A3 3333/4885 |
| US-20030078279-A1 | Spiropiperidine compounds as ligands for ORL-1receptor | OPRL1, OPRD1, OXER1 | SIGMAR1 13/4885EBP 1462/4885SLC18A3 3251/4885 |
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | OPRL1, OXER1, OGFRL1 | SIGMAR1 11/4885EBP 2742/4885SLC18A3 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.